NASDAQ: ANAB · Life Sciences · 4 alerts · CIK 1370053
Share price
$45.73Close, Nov 16
Market cap
$1.37B
Shares outstanding
29.9MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Anaptysbio, Inc filings on SEC EDGAR ↗
AnaptysBio reported net income of $3.9 million for the quarter ended September 30, 2026, compared to $15.1 million in the prior year period. The company's financial structure has shifted significantly following the spin-off of its Biopharma segment, which is now presented as discontinued operations.
AnaptysBio reported financial results for the fiscal first quarter ended September 30, 2026, highlighted by $1.0 billion in global net sales of Jemperli for the first nine months of 2026. The company is currently awaiting a court judgment in its litigation against GSK and Tesaro, where it is seeking the reversion of Jemperli rights as a remedy.
Counterparty
GSK
“Jemperli’s continued commercial growth in endometrial cancer, with global net sales reaching $1 billion through September 30, 2026, and its recent U.S. approval in adults with stage II and III MSI-H/dMMR locally advanced rectal cancer reinforce our confidence in its long-term potential in monotherapy indications.”
Daniel Faga, president and chief executive officer
“We remain focused on protecting and returning the value of our financial collaborations to shareholders as we approach a judgment in our litigation with GSK and Tesaro in calendar Q4 2026 or Q1 2027 and the FDA target action date for Quimilza in December 2026.”
Daniel Faga, president and chief executive officer
AnaptysBio reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, highlighted by $644 million in global net sales for Jemperli, representing 34% year-over-year growth. The company is awaiting a court judgment in its litigation with GSK and Tesaro expected by Q1 2027 and anticipates FDA approval for Quimilza in December 2026.
Counterparty
GSK
Term
Q2 2026
“Jemperli continues to demonstrate robust year-over-year growth with major catalysts within the next 6 months including further sales acceleration ex-US, anticipated FDA approval of Jemperli in monotherapy in dMMR/MSI-H neoadjuvant rectal cancer, as well as a judgement expected in our litigation with GSK and Tesaro.”
Daniel Faga, president and chief executive officer